Bakuchiol is not FDA-approved as a drug ingredient, nor does it need to be for use in a cosmetic toner. In the United States, cosmetics are regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and do not require pre-market approval from the FDA — they must simply be safe for their intended use and accurately labeled. Bakuchiol appears on no FDA restricted or prohibited ingredient list and is widely used in marketed cosmetics without regulatory issue.
Retinol is similarly classified as a cosmetic ingredient in the US when used at concentrations typically found in OTC skincare (0.01%–1%) without drug claims. However, the moment your label or marketing copy attributes a specific therapeutic outcome to retinol — treating a disease, reversing wrinkles as a drug action, or making a drug claim like 'clinically repairs photodamaged skin cells' — FDA may consider your product a drug requiring a New Drug Application (NDA). The practical rule: cosmetic claims describe how a product makes skin look or feel ('visibly reduces the appearance of fine lines'), not how it changes the biological structure or function of skin.
For bakuchiol specifically, since it is often marketed as a 'plant-based retinol alternative,' be careful not to imply it is a retinoid or has identical drug-level pharmacological activity to tretinoin. Claims like 'bakuchiol visibly smooths and tones skin' are solid cosmetic territory. Claims like 'bakuchiol stimulates collagen synthesis at the cellular level' edge toward drug territory.
In the EU, the regulatory picture for retinol tightened significantly. The EU Scientific Committee on Consumer Safety (SCCS) published guidance restricting retinol in face products to 0.3% for general consumer use and 0.05% in body lotion. Bakuchiol carries no such restriction under EU Cosmetics Regulation 1223/2009 as of 2024, making it an attractive alternative for brands targeting European markets.
In the UK post-Brexit, MHRA applies similar principles to the EU on retinol concentration limits. Canada (Health Canada) and Australia (TGA) follow broadly similar cosmetic vs. drug distinction logic to the US, though specific claim review differs.
The practical takeaway: use bakuchiol confidently in your formula and label it accurately in your INCI list. Keep all claims cosmetic in nature. If you add retinol, stay under 0.3% for EU markets and keep language appearance-focused everywhere. Have your label copy reviewed by a regulatory consultant before going to print — this review typically costs $300–$800 and is among the highest-ROI steps a new brand can take. AJ Cosmo Labs connects founders with regulatory consultants alongside contract manufacturers so you can get both conversations running in parallel.
Read the full guide on Private Label Bakuchiol Retinol Toner Manufacturer Low MOQ →